- Home
- SNCY vs SPRY Comparison
SNCY vs SPRY Comparison
Compare SNCY & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNCY | SPRY |
|---|---|---|
| Founded | 1982 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 867.0M | 823.2M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SNCY | SPRY |
|---|---|---|
| Price | $16.17 | $7.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $19.50 | ★ $40.00 |
| AVG Volume (30 Days) | 627.1K | ★ 1.7M |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $1,126,769,000.00 | $84,278,000.00 |
| Revenue This Year | $12.27 | $87.40 |
| Revenue Next Year | $7.51 | $81.64 |
| P/E Ratio | $37.60 | ★ N/A |
| Revenue Growth | ★ 4.74 | N/A |
| 52 Week Low | $10.14 | $6.66 |
| 52 Week High | $22.29 | $18.63 |
Technical Indicators
Market Signals| Indicator | SNCY | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 45.66 | 35.06 |
| Support Level | $15.36 | $6.66 |
| Resistance Level | $17.93 | $8.61 |
| Average True Range (ATR) | 0.65 | 0.52 |
| MACD | 0.05 | -0.10 |
| Stochastic Oscillator | 49.16 | 14.57 |
Price Performance
Historical ComparisonAbout SNCY Sun Country Airlines Holdings Inc.
Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.